Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
about
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancerThe impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisBreast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Strategies for power calculations in predictive biomarker studies in survival dataPrognostic value of gene signatures and proliferation in lymph-node-negative breast cancerA blood-based proteomic classifier for the molecular characterization of pulmonary nodules.Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.A REST derived gene signature stratifies glioblastomas into chemotherapy resistant and responsive diseaseRole of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.Integrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription ProfilingAgreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancerSignatures of tumor-immune interactions as biomarkers for breast cancer prognosisPopulation-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomasCost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel.Integrating breast cancer genetics into clinical practice.Pitfalls in outcome prediction of breast cancer.Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?Biomarker assessment and molecular testing for prognostication in breast cancer.Clinical utility of gene-expression signatures in early stage breast cancer.Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.The Relationship of Race, Oncotype DX, and Ki67 in a Population Highly Screened For Breast Cancer.Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients.[Translational research and diagnostics for breast cancer].Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study
P2860
Q21089802-1C9292C7-5901-47B6-9A78-C4B3A75C6FA3Q26861418-8ADE2364-3B52-4F6D-9147-45B9DC60F620Q30245184-68E5AA2F-67CB-4F01-98D6-B192F7BC0B1FQ31132692-D1751313-1881-426D-9989-2566DC1F9D46Q31152670-93968F30-AC39-47C5-8D91-2893B1D27D51Q33968948-2ABBDDA9-A6EE-4ABC-8386-EB2FE5940C2CQ34341066-82FB5D3C-D5C3-4B66-B694-D5CA564EB069Q34502522-5A432E5B-73BF-4166-9017-2227E0AA918EQ34653166-8972C575-898F-4F70-925F-21705E69843DQ35558070-030B43AB-0B21-4C9B-944E-A01DE3849078Q35709269-012E5FA6-6486-40E4-A14E-B27DFF15926CQ35799611-4F46A4C8-CB32-4027-B0B4-0267FD237FF1Q35913234-9D72CF97-617E-4590-9821-5ED86A33C04CQ36097503-2E429337-51E6-438C-BF1B-FF3261646EBFQ36253304-90B27CFD-6F9A-4112-B550-573FC8B63DFCQ36253744-00FA6D36-8112-4715-AA77-3B8C236882AAQ36594068-C026B6EA-380E-4865-8434-6FA42766712DQ37095310-870E3FBA-47CE-4721-A6B3-923AB4ACE507Q37199779-451EE0E0-F41C-4B4E-BB81-551C2B8BE24DQ37570901-CB83DEC1-B850-481F-8B69-F48624F4EB90Q37862646-5C12C294-8009-40A6-A123-0D66A8D7476DQ37968654-4FF8FB9B-A90D-496F-8B8A-E0D6A3FE7B44Q38101747-526436FF-A68C-466D-9B5C-20189641E1FBQ38254913-41D52E2F-E85A-4997-957D-751613F6835CQ38696790-A230857B-AC36-4F44-9E8D-A0FF164A33D2Q38754717-03E79F15-60E0-4043-9F18-CBF7B1CBB1B3Q38805436-31DDA057-0FC7-4A71-8BE5-58C0A800F436Q39015485-5E3D80A8-D084-4783-B17A-A451F169E4D7Q40146584-40548056-D11F-4C15-BFB0-F4BAED591416Q46162590-51F5CD18-5D1A-4169-A5E5-447A5E6489B8Q48136899-7F3A00D7-201B-4756-BF4F-7D070018B463Q50921836-097C1637-4320-4D38-91FE-C445A06FFEF5Q51035386-7FFC4188-035D-4155-8153-40ED61D35DF2Q52878728-9B565AFA-90B9-4C4F-BEFB-4FB8767D5782Q52935837-12760266-9B67-4BAC-99DB-9B3CC3A9F55EQ54477697-8C3ED88A-6C53-4F14-A3DC-2D73C71989A5Q57135067-DCED5478-8417-4F65-A728-740C9C69A43A
P2860
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Utility of oncotype DX risk es ...... node-negative breast cancers.
@ast
Utility of oncotype DX risk es ...... node-negative breast cancers.
@en
Utility of oncotype DX risk es ...... node-negative breast cancers.
@nl
type
label
Utility of oncotype DX risk es ...... node-negative breast cancers.
@ast
Utility of oncotype DX risk es ...... node-negative breast cancers.
@en
Utility of oncotype DX risk es ...... node-negative breast cancers.
@nl
prefLabel
Utility of oncotype DX risk es ...... node-negative breast cancers.
@ast
Utility of oncotype DX risk es ...... node-negative breast cancers.
@en
Utility of oncotype DX risk es ...... node-negative breast cancers.
@nl
P2093
P2860
P356
P1433
P1476
Utility of oncotype DX risk es ...... node-negative breast cancers.
@en
P2093
Ana M Gonzalez-Angulo
Catherine M Kelly
Gabriel N Hortobagyi
Giampaolo Bianchini
Jennifer K Litton
Lajos Pusztai
Savitri Krishnamurthy
P2860
P304
P356
10.1002/CNCR.25269
P407
P577
2010-11-01T00:00:00Z